225Ac-labeled CD33-targeting antibody reverses resistance to Bcl-2 inhibitor venetoclax in acute myeloid leukemia models.

Ravendra GargKevin J H AllenWojciech DawickiEileen M GeogheganDale L LudwigEkaterina Dadachova

Published in: Cancer medicine (2020)

There results suggest that the combination of 225 Ac-lintuzumab with venetoclax is a promising therapeutic strategy for the treatment of patients with venetoclax-resistant AML. Clinical trial of this combination therapy (NCT03867682) is currently ongoing.

Keyphrases

combination therapy
chronic lymphocytic leukemia
clinical trial
acute myeloid leukemia
open label
cancer therapy
pet imaging
double blind
allogeneic hematopoietic stem cell transplantation
nk cells
pet ct